Last $22.88 USD
Change Today -0.20 / -0.87%
Volume 391.5K
GMED On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

globus medical inc - a (GMED) Snapshot

Open
$23.06
Previous Close
$23.08
Day High
$23.06
Day Low
$22.72
52 Week High
03/19/14 - $27.14
52 Week Low
08/6/14 - $17.45
Market Cap
2.2B
Average Volume 10 Days
491.5K
EPS TTM
$0.96
Shares Outstanding
70.6M
EX-Date
--
P/E TM
23.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for GLOBUS MEDICAL INC - A (GMED)

globus medical inc - a (GMED) Related Businessweek News

No Related Businessweek News Found

globus medical inc - a (GMED) Details

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. It offers approximately 120 products that address an array of spinal pathologies, anatomies, and surgical approaches. The company’s fusion products are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions. Its disruptive technology products provide material improvements to fusion procedures, such as minimally invasive surgical techniques, as well as new treatment alternatives, which include motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous process spacer products, and advanced biomaterials technologies; and interventional pain management solutions, including treatments for vertebral compression fractures. The company has received pre-market approval for SECURE-C Cervical Artificial Disc; and conducting other clinical trials for ACADIA Facet Replacement System, a motion preserving anatomic reconstruction of the facet joint intended for the treatment of spinal stenosis, as well as TRIUMPH Lumbar Disc, a motion preserving disc replacement inserted obliquely into the disc space from a posterolateral approach to address posterior spinal pathology and maintain important anterior anatomical structures. Globus Medical, Inc. sells its implants and related disposables primarily to hospitals. The company markets and sells its products through sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.

850 Employees
Last Reported Date: 03/14/14
Founded in 2003

globus medical inc - a (GMED) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $389.7K
President, Interim Chief Financial Officer, C...
Total Annual Compensation: $324.8K
Co-Founder, Senior Vice President of Operatio...
Total Annual Compensation: $227.3K
Executive Vice President of US Sales
Total Annual Compensation: $297.4K
Executive Officer
Total Annual Compensation: $329.6K
Compensation as of Fiscal Year 2013.

globus medical inc - a (GMED) Key Developments

Globus Medical, Inc. Launches ALTERA, New Minimally Invasive Fully Articulating Expandable Spacer for Spinal Fusion

Globus Medical, Inc. announced the launch of ALTERA(TM), the first new minimally invasive fully articulating expandable spacer for spinal fusion. Designed for restoring lordosis and maintaining sagittal balance while reducing the challenges of insertion, the spacer is inserted at a minimized height, articulated into an anterior position, and then expanded vertically to optimize fit. The company is showcasing ALTERA(TM) as well as several recently launched products at the North American Spine Society (NASS) Annual Meeting, being held in San Francisco this week, Booth #1119. ALTERA(TM) is the latest addition to company's family of expandable spacers, and delivers the benefits of minimized insertion height, continuous expansion and optimized fit. Because of the articulation into anterior placement and the option for 8deg or 15deg profile angles, ALTERA(TM) optimizes lordosis compared to standard static transforaminal lumbar interbody fusion (TLIF) crescent-shaped spacers. Additionally, ALTERA(TM) allows for in-situ delivery of autogenous bone graft into, as well as around, the implant after it has been expanded. The ALTERA(TM) Spacer is an interbody fusion device intended for use in patients with degenerative disc disease (DDD) at one or two contiguous levels of the lumbosacral spine (L2-S1). DDD is defined as discogenic back pain with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had at least six (6) months of non-operative treatment. In addition, these patients may have up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s). The ALTERA(TM) Spacer is to be filled with autogenous bone graft material. These devices are intended to be used with supplemental fixation.

Globus Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Globus Medical, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, sales were $117.787 million against $107.187 million a year ago. Operating income was $34.923 million against $29.503 million a year ago. Income before income taxes was $34.799 million against $29.700 million a year ago. Net income was $23.061 million or $0.24 per diluted share against $20.310 million or $0.22 per diluted share a year ago. EBITDA was $39.991 million against $34.413 million a year ago. Adjusted EBITDA was $41.961 million against $35.765 million a year ago. Non-GAAP net income was $23.091 million or $0.24 per diluted share against $20.375 million or $0.22 per diluted share a year ago. Non-GAAP free cash flow was $32.217 million against $28.038 million a year ago. For the nine months, sales were $345.570 million against $319.214 million a year ago. Operating income was $98.718 million against $69.926 million a year ago. Income before income taxes was $99.164 million against $70.181 million a year ago. Net income was $64.847 million or $0.68 per diluted share against $47.627 million or $0.51 per diluted share a year ago. Net cash provided by operating activities was $77.227 million against $60.813 million a year ago. EBITDA was $114.644 million against $84.056 million a year ago. Adjusted EBITDA was $124.170 million against $107.609 million a year ago. Non-GAAP net income was $67.375 million or $0.71 per diluted share against $60.340 million or $0.64 per diluted share a year ago. Non-GAAP free cash flow was $61.568 million against $42.338 million a year ago.

Globus Medical, Inc. Announces Management Changes

Globus Medical Inc. announced the resignation of Rick Baron, senior vice president and chief financial officer. Baron, who is resigning to pursue other interests, will remain with the company to assist with the transition during the search for his replacement. Dave Demski, the company's president and chief operating officer, will assume the role of CFO on an interim basis. Demski previously served as the company's CFO from 2003 until his promotion to COO in 2008.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GMED:US $22.88 USD -0.20

GMED Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Integra LifeSciences Holdings Corp $48.75 USD -0.06
K2M Group Holdings Inc $18.82 USD +0.17
LDR Holding Corp $33.02 USD -0.57
NuVasive Inc $43.97 USD -0.37
Orthofix International NV $28.18 USD -0.12
View Industry Companies
 

Industry Analysis

GMED

Industry Average

Valuation GMED Industry Range
Price/Earnings 25.6x
Price/Sales 4.7x
Price/Book 3.9x
Price/Cash Flow 25.4x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLOBUS MEDICAL INC - A, please visit www.globusmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.